UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): June 2, 2011

 

 

TRIUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-34828   20-1320630

(State of incorporation

or organization)

 

(Commission

file number)

 

(I.R.S. Employer

Identification Number)

6310 Nancy Ridge Drive, Suite 101

San Diego, CA

  92121
(Address of principal executive offices)   (Zip code)

Registrant’s telephone number, including area code: (858) 452-0370

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

Our 2011 Annual Meeting of Stockholders was held on June 2, 2011. We had 23,667,333 shares of common stock outstanding and entitled to vote as of April 12, 2011, the record date for the Annual Meeting. At the Annual Meeting, 18,965,057 shares of common stock were present in person or represented by proxy for the two proposals specified below.

At the Annual Meeting, stockholders:

(1)        elected Brian G. Atwood, David S. Kabakoff, Ph.D., Nina Kjellson and Brendan O’Leary, Ph.D. as Class I directors to hold office until the 2014 Annual Meeting of Stockholders; and

(2)        ratified the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2011.

The following sets forth detailed information regarding the final results of the voting for the Annual Meeting:

Proposal 1. Election of Directors

 

Name

 

Votes For

 

Votes Withheld

 

Broker Non-Votes

Brian G. Atwood

  17,052,016   2,218   1,910,823

David S. Kabakoff, Ph.D.

  17,052,016   2,218   1,910,823

Nina Kjellson

  17,050,334   3,900   1,910,823

Brendan O’Leary, Ph.D.

  17,050,534   3,700   1,910,823

Proposal 2. Ratification of the selection of Independent Registered Public Accounting Firm

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

18,954,327

  8,061   2,669  


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Trius Therapeutics, Inc.
Dated: June 3, 2011     By:   /s/    John P. Schmid        
    Name:   John P. Schmid
    Title:   Chief Financial Officer